NLS Pharmaceutics (NLSP) Competitors $1.46 +0.03 (+2.10%) Closing price 04/17/2025 04:00 PM EasternExtended Trading$1.44 -0.02 (-1.64%) As of 04/17/2025 05:48 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisChartCompetitorsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock NLSP vs. LGVN, PULM, RVPH, MURA, NAII, ENLV, PMN, RNXT, QTTB, and GRCEShould you be buying NLS Pharmaceutics stock or one of its competitors? The main competitors of NLS Pharmaceutics include Longeveron (LGVN), Pulmatrix (PULM), Reviva Pharmaceuticals (RVPH), Mural Oncology (MURA), Natural Alternatives International (NAII), Enlivex Therapeutics (ENLV), ProMIS Neurosciences (PMN), RenovoRx (RNXT), Q32 Bio (QTTB), and Grace Therapeutics (GRCE). These companies are all part of the "pharmaceutical products" industry. NLS Pharmaceutics vs. Longeveron Pulmatrix Reviva Pharmaceuticals Mural Oncology Natural Alternatives International Enlivex Therapeutics ProMIS Neurosciences RenovoRx Q32 Bio Grace Therapeutics Longeveron (NASDAQ:LGVN) and NLS Pharmaceutics (NASDAQ:NLSP) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their profitability, dividends, risk, earnings, analyst recommendations, valuation, media sentiment, institutional ownership and community ranking. Does the media favor LGVN or NLSP? In the previous week, NLS Pharmaceutics had 1 more articles in the media than Longeveron. MarketBeat recorded 2 mentions for NLS Pharmaceutics and 1 mentions for Longeveron. Longeveron's average media sentiment score of 0.92 beat NLS Pharmaceutics' score of 0.50 indicating that Longeveron is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Longeveron 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive NLS Pharmaceutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Does the MarketBeat Community believe in LGVN or NLSP? Longeveron received 10 more outperform votes than NLS Pharmaceutics when rated by MarketBeat users. Likewise, 94.74% of users gave Longeveron an outperform vote while only 57.14% of users gave NLS Pharmaceutics an outperform vote. CompanyUnderperformOutperformLongeveronOutperform Votes1894.74% Underperform Votes15.26%NLS PharmaceuticsOutperform Votes857.14% Underperform Votes642.86% Which has more risk & volatility, LGVN or NLSP? Longeveron has a beta of 0.39, meaning that its share price is 61% less volatile than the S&P 500. Comparatively, NLS Pharmaceutics has a beta of -0.21, meaning that its share price is 121% less volatile than the S&P 500. Which has higher valuation and earnings, LGVN or NLSP? NLS Pharmaceutics has lower revenue, but higher earnings than Longeveron. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioLongeveron$2.39M9.11-$21.41M-$6.28-0.23NLS PharmaceuticsN/AN/A-$12.17MN/AN/A Is LGVN or NLSP more profitable? NLS Pharmaceutics has a net margin of 0.00% compared to Longeveron's net margin of -967.49%. NLS Pharmaceutics' return on equity of 0.00% beat Longeveron's return on equity.Company Net Margins Return on Equity Return on Assets Longeveron-967.49% -142.43% -100.84% NLS Pharmaceutics N/A N/A N/A Do analysts recommend LGVN or NLSP? Longeveron presently has a consensus price target of $8.67, indicating a potential upside of 493.61%. Given Longeveron's stronger consensus rating and higher probable upside, analysts clearly believe Longeveron is more favorable than NLS Pharmaceutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Longeveron 0 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 1 Strong Buy rating(s) 3.25NLS Pharmaceutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Do insiders & institutionals believe in LGVN or NLSP? 10.0% of Longeveron shares are owned by institutional investors. 19.1% of Longeveron shares are owned by insiders. Comparatively, 16.4% of NLS Pharmaceutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth. SummaryLongeveron beats NLS Pharmaceutics on 11 of the 16 factors compared between the two stocks. Get NLS Pharmaceutics News Delivered to You Automatically Sign up to receive the latest news and ratings for NLSP and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart NLSP vs. The Competition Export to ExcelMetricNLS PharmaceuticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$5.25M$6.44B$5.30B$7.34BDividend YieldN/A3.23%5.45%4.30%P/E RatioN/A6.8921.8617.80Price / SalesN/A230.56380.5497.74Price / CashN/A65.6738.2634.64Price / BookN/A5.936.453.98Net Income-$12.17M$142.99M$3.22B$247.81M1 Month Performance-6.41%-13.57%-9.71%-7.84%1 Year Performance1,000.23%-8.90%11.51%1.60% NLS Pharmaceutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)NLSPNLS PharmaceuticsN/A$1.46+2.1%N/A+1,000.2%$5.25MN/A0.006Short Interest ↓LGVNLongeveron3.0312 of 5 stars$1.35-3.6%$8.67+542.0%-27.4%$20.15M$2.39M-0.2120News CoveragePULMPulmatrixN/A$5.52+2.2%N/A+224.1%$20.15M$7.81M-2.0920Gap DownRVPHReviva Pharmaceuticals2.2854 of 5 stars$0.60+13.2%$10.00+1,566.7%-74.1%$20.07MN/A-0.545Upcoming EarningsMURAMural Oncology2.5991 of 5 stars$1.16+2.7%$13.00+1,020.7%-24.4%$19.98MN/A-0.13119Options VolumeNAIINatural Alternatives International1.2916 of 5 stars$3.12-5.7%N/A-59.0%$19.34M$121.85M-2.42290Analyst ForecastShort Interest ↓Gap UpENLVEnlivex Therapeutics3.2829 of 5 stars$0.89+0.2%$10.00+1,023.6%-38.2%$19.05MN/A-0.9170Short Interest ↓PMNProMIS Neurosciences2.8742 of 5 stars$0.58-5.1%$6.00+929.7%-67.8%$19.05MN/A-5.835RNXTRenovoRx2.0351 of 5 stars$0.79-10.4%$6.00+659.5%-16.4%$18.96M$43,000.00-1.396Short Interest ↑News CoverageGap DownHigh Trading VolumeQTTBQ32 Bio1.8085 of 5 stars$1.53-6.7%$24.71+1,515.3%-91.3%$18.66M$-6,651,000.00-0.1139News CoverageGRCEGrace TherapeuticsN/A$1.80-10.0%$12.00+566.7%N/A$18.25MN/A-1.55N/AGap Down Related Companies and Tools Related Companies Longeveron Alternatives Pulmatrix Alternatives Reviva Pharmaceuticals Alternatives Mural Oncology Alternatives Natural Alternatives International Alternatives Enlivex Therapeutics Alternatives ProMIS Neurosciences Alternatives RenovoRx Alternatives Q32 Bio Alternatives Grace Therapeutics Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:NLSP) was last updated on 4/19/2025 by MarketBeat.com Staff From Our PartnersElon Set to Shock the World by May 1st ?Tech legend Jeff Brown recently traveled to the industrial zone of South Memphis to investigate what he believ...Brownstone Research | Sponsored[Action Required] Claim Your FREE IRS Loophole GuideThis shouldn't surprise anyone who's been paying attention, but... Pres. Trump may be about to unleash the ...Colonial Metals | SponsoredGet Your Bank Account “Fed Invasion” Ready with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredAltucher: Turn $900 into $108,000 in just 12 months?We are entering the final Trump Bump of our lives. But the biggest returns will not be in the stock market.Paradigm Press | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowMy friends Joel and Adam have a simple motto: "For us, it's always a bull market." That’s because their 92%...Crypto Swap Profits | SponsoredGold Hits New Highs as Global Markets SpiralWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | SponsoredClaim Your FREE Protection GuideIn the final days of his first term, Trump quietly left open an "off the books" wealth-protection loophole hid...American Alternative | SponsoredElon Musk Confirms: Tesla’s Optimus is Replacing Workers… and Heading to MarsElon Musk just confirmed Tesla’s robot will go to Mars. But on Earth, it may trigger a trillion-dollar tech sh...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding NLS Pharmaceutics Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. Share NLS Pharmaceutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy NLSP Stock Free NLSP Stock Alerts